Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
Launched by SHANGHAI ZHONGSHAN HOSPITAL · Dec 5, 2014
Trial Information
Current as of September 08, 2025
Unknown status
Keywords
ClinConnect Summary
The prognosis information of the patients with acute variceal bleeding will be collected, including hemostasis rate, early rebleeding rate, mortality, complications, severity adverse events, economic burdens and quality of life, when terlipressin or high dose somatostatin/octreotide is used as salvation to patients fail to achieve initial hemostasis.The results may help gastroenterologists to make decisions when administering vasoactive medicines to those suffered from acute variceal bleeding.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cirrhosis patients admitted to Emergency Department because of acute variceal bleeding
- Exclusion Criteria:
- • No signs of variceal bleeding are found by endoscopy or portal hypertensive gastropathy is responsible for the bleeding
- • Patients undergo endoscopy after 72h from the beginning of acute variceal bleeding
- • Patients with hepatorenal syndrome
- • Patients with ischemia organic cardiopathy (including myocardial infarction or unstable angina pectoris) or myocardial ischemia indicated by ECG in the past 6 months
- • Patients allergic to/with contraindications of vasoactive drugs
About Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Shiyao Chen, Professor
Study Chair
Shanghai Zhongshan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials